[
  {
    "ts": null,
    "headline": "1 Dividend Stock Down 30% to Buy and Hold for the Next Decade",
    "summary": "Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year.  Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer.  The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise.",
    "url": "https://finnhub.io/api/news?id=bfe43119fdec1c0469dadd3818f5bd019208422bf10292ddc9bc6afdc7f55309",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741515600,
      "headline": "1 Dividend Stock Down 30% to Buy and Hold for the Next Decade",
      "id": 133186693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year.  Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer.  The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise.",
      "url": "https://finnhub.io/api/news?id=bfe43119fdec1c0469dadd3818f5bd019208422bf10292ddc9bc6afdc7f55309"
    }
  }
]